NIH Asks AIDS Labs to Tighten Safety

WASHINGTON—Federal biosafety guidelines for laboratories handling the AIDS virus are appropriate, a team of virus safety experts has concluded after investigating labs working with large amounts of highly concentrated AIDS virus. But workers need to better understand how and why the practices should be followed. The four-member group, formed last month after NIH announced that an unidentified lab worker was infected while working with the virus, spent two weeks at the dozen or so NIH

Written byAmy Mcdonald
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

WASHINGTON—Federal biosafety guidelines for laboratories handling the AIDS virus are appropriate, a team of virus safety experts has concluded after investigating labs working with large amounts of highly concentrated AIDS virus. But workers need to better understand how and why the practices should be followed.

The four-member group, formed last month after NIH announced that an unidentified lab worker was infected while working with the virus, spent two weeks at the dozen or so NIH contract facilities and AIDS antibody test producers that work with large quantities of concentrated virus.

“It’s very important that labs fully accept their role of managing safety, which implies more than just a knowledge of basic practices outlined by the CDC [Centers for Disease Control] and NIH,” said Emmett Barkley, director of NIH’s Division of Engineering Services, who led the investigation. “The techniques required to handle a pathogen cannot be mastered by reading a safety ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies